Torrent Pharma surpasses sales records in Q4 2026, yet profit margin concerns arise due to a dip in key financial indicators.

Torrent Pharma reached an unprecedented high of Rs 4,698.8 on May 25, 2026, surpassing previous records. The stock demonstrated robust performance, outpacing the Sensex and exhibiting positive momentum over various time periods.

Torrent Pharma anticipates robust growth in India by focusing on semaglutide, Curatio, and their chronic disease portfolio. If geopolitical issues can be avoided, an optimistic outlook for organic growth is predicted.

Torrent Pharmaceuticals' Q4 FY26 results surpassed expectations, largely due to the consolidation of JB Pharma. However, financial advisor Nirmal Bang maintains a 'Hold' stance on the company, setting a target price of Rs 4,898, as they see minimal growth potential given the current market valuations.

Torrent Pharma aims to generate approximately INR 450 crore in synergies from their acquisition of JB Pharma within three years, with potential savings of up to 80% by the second year and ongoing benefits in the third year.

Eicher Motors soars after positive management updates, approaching a record high on the BSE. Torrent Pharma gains post robust results. Sterlite Tech rises due to specific news, while Divi's Lab weakens. The BSE approaches a lifetime high, with GAIL trending as well.

Morgan Stanley maintains a balanced stance on Torrent Pharma, predicting a price target of INR 4580, driven by anticipated 15% growth in India and a matching Q4 EBITDA. Meanwhile, JB Pharma synergies are projected to bring in revenues between INR 4-4.5 billion, with Semaglutide securing a 38% market share and FY27 sales expectations at INR 2-2.5 billion.

Seven companies, including Abbott India, Torrent Pharma, and Sun Pharma, have announced their dividend record dates. This means shareholders of these companies will receive their dividends soon, as stated in the companies' respective announcements.

Morgan Stanley maintains its stance on Torrent Pharma as neutral and has set a new price target of INR 4,580, suggesting potential growth for investors.

Torrent Pharma anticipates a modest, single-digit increase in their US sales for the coming year. On the other hand, their Brazilian operations are projected to experience a substantial growth of 10-15%.

The Nifty index experienced a significant boost of around 260 points, approaching 23,980, with PSU banks playing a key role in the surge. Fuel companies saw gains due to price increases, while Eicher Motors, Torrent Pharma, and GreenLam posted earnings-driven growth.

Hindalco's Q4 earnings dropped by over half despite a revenue increase, while NTPC and Eicher Motors saw substantial net profit gains. Eicher Motors reported its highest-ever Q4 net profit, with Torrent Pharma experiencing a significant decrease in profits.

Jefferies remains optimistic about Torrent Pharma, reiterating a Buy rating and setting a target price of ₹5350. This confidence stems from projected 15% year-on-year growth in India, despite core performance being consistent without JB Pharma consolidation. The firm also highlights that cost synergies are progressing as anticipated.

Torrent Pharma experienced a 27% decrease in profit after tax (PAT) during the fourth quarter, reaching ₹364 crores. This reduction is attributed to significant expenses incurred as exceptional items.

Torrent Pharma experienced a surge, reaching new 52-week highs, indicating strong investor interest, despite no significant recent events influencing its stock performance.

Torrent Pharma shows impressive growth in the fourth quarter, with a 42% increase in sales and an even higher 38% jump in EBITDA compared to last year, as per Goldman Sachs' latest report.

Torrent Pharma plans to increase its field force in India to 7,500 by FY27, marking a pause in expansion following the JB MR merger. The company anticipates strong sales for semaglutide, projecting revenues of INR 200-250 crore in the first year, surpassing sitagliptin's current market share of INR 70-75 crore.

Torrent Pharma's Q4 earnings show a significant 40% increase in revenue and EBITDA, mainly attributed to a robust performance in the Indian market. The introduction of generic semaglutide has contributed to this growth, although increased acquisition costs have impacted net profit.

The focus of the Nifty bulls is on West Asia negotiations, with optimism for a positive outcome that could bolster market clarity and momentum. Notable companies like Hindalco, Eicher Motors, and Torrent Pharma are set to release their earnings, which may significantly impact their stock prices. The Nifty's support level remains at 23,700, while resistance is observed at 23,850.

Torrent Pharma experienced a significant 27% drop in their Q4 profits during the March 2026 quarter, signifying a challenging financial period for the company.

Torrent Pharma has announced May 29, 2026, as the cutoff date for eligibility for its final dividend for FY 2025-26. If approved, this dividend would apply to its shares of INR 5 each, in accordance with Regulation 42.

Torrent Pharma announces a final dividend of Rs 9 per share for the fiscal year 2026, following clean audits and approved results. Additionally, they propose an interim dividend of Rs 29 per share and a QIP worth Rs 5,000 crores. The company has also acquired JB Pharma's stake and is currently in the process of merging with it.

Torrent Pharma saw a significant increase in its Q4 revenue, reaching INR 4,197 crore, marking a 42% jump compared to the previous year. The fiscal year 2025-2026 revenues climbed by 21% to INR 13,980 crore. Remarkably, India was the primary driver of growth, recording a 43% increase in Q4, while the US and Germany experienced upticks of 31% and 16%, respectively.

Today, Sun Pharma, Hindalco, Eicher Motors, Torrent Pharma, and NTPC Green are set to release their Q4 results, with ITC, LIC, GAIL, Emami, Max Health, JSW Cement, Va Tech, and 3M India also under the spotlight for their financial performances. Investors will closely monitor these companies' results to gauge their performance in the recent quarter.

Torrent Pharma's forthcoming Q4 earnings might reveal a squeezing of profit margins, hinting at potential challenges in their operations or pricing strategy. Investors should stay attentive for more detailed updates and company commentary.

Torrent Pharma experienced a significant block deal on the NSE, amounting to approximately INR 28.26 crores, with each share trading at around INR 4,342.90, representing a trade of over 65,000 shares.

Torrent Pharma announces that its merger with JB Chemicals is nearing completion, with a final decision anticipated following the June hearing, suggesting a likely conclusion within 1-2 months.

Torrent Pharmaceuticals sets a new record at Rs 4,486 (May 11, 2026), indicating robust financial health and impressive market performance.

Experts recommend six stocks for quick profits, such as Coal India, Torrent Pharma, Zydus Lifesciences, Emcure Pharmaceuticals, and Welspun Corp, given the subdued market atmosphere. Sharda Cropchem's positive technical signals suggest continued momentum.

Today, focus is on the Q4 results of MCX, Vodafone Idea, and Torrent Pharma. These stocks could see substantial price fluctuations due to key news releases.

Increased open interest for Torrent Pharma has more than doubled, reaching 24,594 contracts - a sign of growing investor enthusiasm towards the pharmaceutical sector as prices approach a 52-week high.

Torrent Pharma is set to offload the Calcigard brand to satisfy Competition Commission of India (CCI) rules following their acquisition by JB Chemicals. The CCI raised concerns over Torrent's dominance in nifedipine market, with a 90% share and higher pricing, necessitating a sale for approval.

ICICI Securities predicts a moderate 7.2% revenue growth for the pharmaceutical sector in Q4 FY26, with EBITDA and PAT forecasted to decrease. Top picks include Sun Pharma, Aurobindo, Alkem, Gland, and Torrent, which could benefit from a domestic focus. Lupin shows signs of resilience.

Torrent Pharmaceuticals' oncology unit in Bileshwarpura passed a US FDA inspection without any issues, indicating the facility meets high-quality standards for manufacturing cancer treatments. This compliance strengthens Torrent's position in the global pharmaceutical market.

Muthoot Finance announces a ₹30 interim dividend per share. Meanwhile, Maruti Suzuki reported increased production and sales in March 2026, due to strong demand for utility vehicles. Lupin debuts dapagliflozin in the US market, while Torrent Pharma's Gujarat oncology unit undergoes USFDA inspection from April 6-10, 2026.

Torrent Pharma obtains US FDA approval, allowing their oncology division to commence operations without any preliminary inspections. This marks a significant milestone in the pharmaceutical industry.

The Indian pharmaceutical sector experienced a significant 8.8% growth in FY26, reaching an impressive Rs 2.46 lakh crore, predominantly driven by the cardiac and anti-diabetic segments. Key players such as Sun Pharma, Abbott, Cipla, Mankind, and Torrent Pharma reported double-digit growth. Notably, Eli Lilly's Mounjaro emerged as a top seller in drug sales during this period.

The US Food and Drug Administration (FDA) has given Torrent Pharma's oncology facility in Bileshwarpura a clean bill of health following an inspection from April 6-10, 2026. The FDA found no issues, indicating that the facility meets all standards for product quality and compliance.

Torrent Pharma's Gujarat oncology plant has successfully passed the USFDA inspection with no issues, marking a significant milestone for the company. In Q3 of FY26, the firm experienced a 26.3% increase in net profit to ₹635 Cr and saw a 14% growth in India revenues to ₹1,798 Cr.

Sun Pharma and Torrent Pharma stand out among large-cap stocks due to their excellent financial health, both earning a perfect Piotroski score of 9. Notably, Sun Pharma's success stems from its robust R&D efforts and global reach, while Torrent Pharma dominates in the Indian and Brazilian markets through growth and strategic acquisitions.